Skip to main content

Schwarzman Stephen A's Form 4 filing

Imago BioSciences, Inc. (IMGO) · filed Jul 20, 2021

Accession no.
0001567619-21-013733
Filed
Jul 20, 2021, 6:05 PM ET
Trade date
Jul 20, 2021
Filing delay
Same day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $2.40M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Schwarzman Stephen ACIK 000107084410% Owner
Blackstone Inc.CIK 000139381810% Owner
Blackstone Group Management L.L.C.CIK 000140407110% Owner
Blackstone Holdings I/II GP L.L.C.CIK 000146469510% Owner
Blackstone Holdings II L.P.CIK 000148487010% Owner
Clarus Lifesciences III, L.P.CIK 000159714310% Owner
Clarus Ventures III GP, L.P.CIK 000162014810% Owner
Blackstone Clarus III L.L.C.CIK 000176220210% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 20, 2021Common StockCConversionAcquired+1,872,217–F1–1,872,217Indirect
Jul 20, 2021Common StockCConversionAcquired+1,155,689–F1–3,027,906Indirect
Jul 20, 2021Common StockCConversionAcquired+197,131–F1–3,225,037Indirect
Jul 20, 2021Common StockPPurchaseAcquired+150,000$16.00+$2,400,0003,375,037Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 20, 2021Common StockCConversionDisposed−1,872,217$0.00$00Indirect
Jul 20, 2021Common StockCConversionDisposed−1,155,689$0.00$00Indirect
Jul 20, 2021Common StockCConversionDisposed−197,131$0.00$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each share of the issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) shares of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on July 20, 2021 and had no expiration date.

Referenced by the price of 3 transactions in Table I.

Remarks

CLARUS LIFESCIENCES III, L.P., By: Clarus Ventures III GP, L.P., its GP, By: Blackstone Clarus III, L.L.C., its GP, By: Blackstone Holdings II L.P., its managing member, By: Blackstone Holdings I/II GP L.L.C., its GP, By: /s/ Tabea Hsi, SMD CLARUS VENTURES III GP, L.P., By: Blackstone Clarus III, L.L.C., its GP, By: Blackstone Holdings II L.P., its managing member, By: Blackstone Holdings I/II GP L.L.C., its GP, By: /s/ Tabea Hsi, Title: Senior Managing Director BLACKSTONE CLARUS III L.L.C., By: Blackstone Holdings II L.P., its managing member, By: Blackstone Holdings I/II GP L.L.C., its general partner, By: /s/ Tabea Hsi, Title: Senior Managing Director BLACKSTONE HOLDINGS II L.P., By: Blackstone Holdings I/II GP L.L.C., its general partner, By: /s/ Tabea Hsi, Title: Senior Managing Director BLACKSTONE HOLDINGS I/II GP L.L.C., By: /s/ Tabea Hsi, Title: Senior Managing Director THE BLACKSTONE GROUP INC., By: /s/ Tabea Hsi, Title: Senior Managing Director BLACKSTONE GROUP MANAGEMENT L.L.C., By: /s/ Tabea Hsi, Title: Senior Managing Director /s/ Stephen A. Schwarzman

Read the full filing on SEC EDGAR (opens in a new tab)